Monitoring B cell response to immunoselected phage-displayed peptides by microarrays.
Successful adaptation of microarray technology for high-throughput screening of proteins requires a large number of purified recombinant proteins, e.g., antibodies for use as capture molecules. Phage surface display technology has been used for the surface expression of proteins, peptides or cDNA repertoires expressed by tumor cells. It does not require protein purification, as recombinant phages can be spotted on glass slides and used in a high-throughput screening format. Biopanning of phage libraries on patient serum antibodies is expected to enrich for antibody-binding phages for the fabrication of diagnostic and/or prognostic B-cell epitope microarrays. In contrast to other immunological techniques, microarrays can measure the antibody levels against different epitopes in a single test. This chapter highlights the recent advances in phage-based microarray technology to profile humoral immune responses in cancer patients.
Department of Immunology, Institute for Cancer Research, The Norwegian Radium Hospital, Rikshopitalet University Hospital Montebello, N-0310 Oslo, Norway.
Lina
L
Cekaite
Eiving
E
Hovig
Mouldy
M
Sioud
D000906:Antibodies / Q000032:analysis / Q000276:immunology*; D001402:B-Lymphocytes / Q000276:immunology; D018985:Epitopes, B-Lymphocyte / Q000032:analysis / Q000276:immunology*; D006801:Humans; D046228:Microarray Analysis / Q000379:methods*; D009369:Neoplasms / Q000175:diagnosis / Q000276:immunology*; D019151:Peptide Library; D044967:Serum / Q000276:immunology
D000906:Antibodies; D018985:Epitopes, B-Lymphocyte; D019151:Peptide Library